Filing Flows › Iradimed (IRMD) › Q3 2026 › vs Q3 2025
Iradimed (IRMD) Q3 2026 vs Q3 2025 (year over year)
Iradimed's revenue rose $3.0M (+14%) from $21.2M in Q3 2025 to $24.2M in Q3 2026. The biggest changes: Total devices revenue +$1.6M (+10%); Disposables +$850K (+21%); Services and other +$371K (+42%). Gross margin 76.3% against 77.8% (-1.5 pts).
Iradimed, Q3 2026: revenue $24.2M (+14% year over year), operating margin 33.6%, net earnings $6.5M, operating cash flow $7.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 76.3% | 77.8% | -1.5 pts |
| Operating margin | 33.6% | 32.2% | +1.4 pts |
| Net margin | 26.9% | 26.3% | +0.6 pts |
| Free cash flow margin | 28.0% | 27.0% | +1.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| MRI Compatible IV Infusion Pumps | $8.7M | $8.3M | $353K | +4% |
| MRI Compatible Patient Vital Signs Monitoring Systems | $8.0M | $6.9M | $1.1M | +17% |
| Ferro Magnetic Detection Systems | $483K | $378K | $105K | +28% |
| Total devices revenue | $17.2M | $15.6M | $1.6M | +10% |
| Disposables | $5.0M | $4.1M | $850K | +21% |
| Services and other | $1.2M | $874K | $371K | +42% |
| Amortized Revenue | $801K | $613K | $188K | +31% |
| Revenue | $24.2M | $21.2M | $3.0M | +14% |
| Gross profit | $18.5M | $16.5M | $2.0M | +12% |
| Cost of revenue | $5.7M | $4.7M | $1.0M | +22% |
| Other income, net | $529K | $464K | $65K | +14% |
| Operating profit | $8.1M | $6.8M | $1.3M | +19% |
| Operating expenses | $10.3M | $9.7M | $656K | +7% |
| Pre-tax earnings | $8.7M | $7.3M | $1.4M | +19% |
| Research & development | $875K | $674K | $201K | +30% |
| Sales & marketing | $4.9M | $4.6M | $278K | +6% |
| General & admin | $4.5M | $4.4M | $177K | +4% |
| Net earnings | $6.5M | $5.6M | $929K | +17% |
| Income tax | $2.2M | $1.7M | $441K | +26% |
| Depreciation & amortization | $412K | $383K | $29K | +8% |
| Share-based compensation | $777K | $666K | $111K | +17% |
| Working capital & other | $698K | −$360K | $1.1M | — |
| Operating cash flow | $7.0M | $7.0M | $11K | +0.2% |
| Free cash flow (company-reported) | $6.8M | $5.7M | $1.1M | +19% |
| Capital Expenditures | $212K | $1.3M | −$1.1M | -83% |
Questions
How much did Iradimed's revenue grow year over year in Q3 2026?
Iradimed's revenue rose $3.0M (+14%) from $21.2M in Q3 2025 to $24.2M in Q3 2026.
What drove Iradimed's revenue change in Q3 2026?
Total devices revenue +$1.6M (+10%); Disposables +$850K (+21%); Services and other +$371K (+42%).